company background image
BXN logo

Bioxyne ASX:BXN Stock Report

Last Price

AU$0.01

Market Cap

AU$20.5m

7D

-23.1%

1Y

-16.7%

Updated

11 Oct, 2024

Data

Company Financials

BXN Stock Overview

A life sciences and consumer health products company, manufactures and distributes consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines in the United Kingdom, Japan, Europe, and Australia.

BXN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Bioxyne Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bioxyne
Historical stock prices
Current Share PriceAU$0.01
52 Week HighAU$0.021
52 Week LowAU$0.004
Beta0.78
11 Month Change-28.57%
3 Month Change100.00%
1 Year Change-16.67%
33 Year Change-56.52%
5 Year Change-47.37%
Change since IPO-94.74%

Recent News & Updates

Recent updates

Shareholder Returns

BXNAU Personal ProductsAU Market
7D-23.1%2.7%0.2%
1Y-16.7%85.1%15.9%

Return vs Industry: BXN underperformed the Australian Personal Products industry which returned 85.1% over the past year.

Return vs Market: BXN underperformed the Australian Market which returned 15.9% over the past year.

Price Volatility

Is BXN's price volatile compared to industry and market?
BXN volatility
BXN Average Weekly Movement33.7%
Personal Products Industry Average Movement13.3%
Market Average Movement8.9%
10% most volatile stocks in AU Market17.5%
10% least volatile stocks in AU Market3.6%

Stable Share Price: BXN's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: BXN's weekly volatility has increased from 25% to 34% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998n/aSam Watsonbioxyne.com

Bioxyne Limited, a life sciences and consumer health products company, manufactures and distributes consumer health products, patented probiotics, health supplements, therapeutic goods, and alternative medicines in the United Kingdom, Japan, Europe, and Australia. The company manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabinoids, cannabis extracts, vitamins, manuka honey, skin care products, and mushroom complexes. It develops various functional food products, such as ingredients; and lactobacillus fermentum VRI-003 for over-the counter gut health immune supplement products.

Bioxyne Limited Fundamentals Summary

How do Bioxyne's earnings and revenue compare to its market cap?
BXN fundamental statistics
Market capAU$20.47m
Earnings (TTM)-AU$12.80m
Revenue (TTM)AU$9.64m

2.1x

P/S Ratio

-1.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BXN income statement (TTM)
RevenueAU$9.64m
Cost of RevenueAU$5.93m
Gross ProfitAU$3.72m
Other ExpensesAU$16.51m
Earnings-AU$12.80m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.0063
Gross Margin38.53%
Net Profit Margin-132.73%
Debt/Equity Ratio1.1%

How did BXN perform over the long term?

See historical performance and comparison